Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations

Eva Geissinger,[1] Petra Sadler,[1] Sabine Roth,[1] Tina Grieb,[1] Bernhard Puppe,[1] Nora Müller,[1] Peter Reimer,[2] Claudia S. Vetter-Kauczok,[3] Jörg Wenzel,[4] Irina Bonzheim,[5] Thomas Rüdiger,[6] Hans Konrad Müller-Hermelink,[1] and Andreas Rosenwald[1]

[1]Institute of Pathology, University of Wuerzburg, Germany; [2]Evangelisches Krankenhaus Essen-Werden, Kliniken Essen Süd, Germany; [3]Dermatologische Klink und Poliklinik, University of Wuerzburg, Germany; [4]Dermatologische Klink und Poliklinik, University of Bonn, Germany; [5]Institute of Pathology, University Hospital Tuebingen, Germany, and [6]Institute of Pathology, Städtisches Klinikum Karlsruhe, Germany

Online Supplementary Table S1. Sources and dilutions of primary antibodies.

Antibody	Clone	Source	Dilution	Pretreatment
CD30	BerH2	Dako	1:80	CA pH 6.0
ALK1	ALK1	Dako	1:80	CA pH 6.0
TcRa/β	8A3	Endogen	1:40	TR
CD3ε	PS1	Novocastra	1:80	CA pH 6.0
CD3γ	C-20	Santa Cruz	1:200	CA pH 6.0
CD3δ	M-20	Santa Cruz	1:200	CA pH 6.0
CD3ζ	6B10.2	Santa Cruz	1:1000	CA pH 6.0
vLAT	FL-233	Santa Cruz	1:300	TR
ZAP-70	2F3.2	Upstate	1:800	CA pH 7.0
NFATc1	7A6	BD	1:400	TR
bcl-10	151	Zymed	1:200	CA pH 6.0
CARD11 (CARMA1)	Rabbit polyclonal	Lifespan Biosciences	1:400	CA pH 6.0
Lck	Y123	Epitomics	1:200	CA pH 6.0
Syk	EP573Y	Epitomics	1:400	CA pH 6.0
ATF1	25C10G	Santa Cruz	1:200	CA pH 6.0
ATF2	C-19	Santa Cruz	1:100	CA pH 6.0
TCF-1	A-79	Santa Cruz	1:100	TR
Lef-1 (TcF-1α)	EPR2029Y	Epitomics	1:100	CA pH 6.0
Ets-1	1G11	Santa Cruz	1:100	TR
c-Jun	H-79	Santa Cruz	1:300	CA pH 6.0
c-Fos	K-25	Santa Cruz	1:1000	CA pH 6.0

Immunohistochemical staining with Advance™ HRP detection kit (K4068) from Dako. BD Bioscience, Heidelberg, Germany; Dako, Hamburg, Germany; Endogen, Woburn, MA USA; Epitomics, Burlingame, CA USA; Lifespan Biosciences, Seattle, WA USA; Monosan, AM Uden, the Netherlands; Novocastra, Newcastle upon Tyne, UK; Santa Cruz, Santa Cruz, California USA; Upstate, Temecula, CA USA; Zymed, South San Francisco, CA USA. Pretreatment: CA: citric acid, TR: target retrieval, S1699, Dako, Hamburg, Germany.

Online Supplementary Table S2. Immunohistochemical staining results of transcription factors regulating TCR expression and TCR/CD3 complex-associated signaling molecules. *P* values are given for comparison of the different disease groups as A = the entire group of primary cutaneous CD30⁺ T-cell lymphoproliferative disorders (n = 19), B1 = ALK⁻ systemic ALCL (n = 38), B2 = ALK⁺ systemic ALCL (n = 33), B = the entire group of systemic ALCL (n = 71), C = PTCL-NOS (n = 20). Significant *P* values are displayed in italics. *P* values comparing A1 = lymphomatoid papulosis (n = 9) and A2 = cutaneous ALCL (n = 10) were not significant for any marker and are not, therefore, detailed. For some markers (ATF-1, TCF-1α/LEF-1, Lck, c-Jun, and c-Fos) fewer cases were evaluable (numbers are indicated in brackets) than reported above due to limited material. The staining results were reported semi-quantitatively (see *Design and Methods* section) and the percentage of cases is indicated. LyP, lymphomatoid papulosis; sALCL, systemic ALCL; cALCL, cutaneous ALCL.

Cases	Staining intensities				*P* values
	0	1	2	3	
ATF-1					
LyP (n=8)	0	0	2 (25%)	6 (75%)	A/B: *P*=0.027
cALCL	0	0	1 (10%)	9 (90%)	B1/B2: *P*=0.459
sALCL ALK-	0	0	16 (42%)	22 (58%)	B1/C: *P*<0.001
sALCL ALK+	0	2 (6%)	14 (42%)	17 (52%)	B2/C: *P*=0.011
PTCL-NOS	0	0	18 (90%)	2 (10%)	B/C: *P*=0.001
ATF-2					
LyP	0	0	0	9 (100%)	A/B: *P*=0.104
cALCL	0	0	0	10 (100%)	B1/B2: *P*=0.197
sALCL ALK-	0	0	3 (8%)	35 (92%)	B1/C: *P*<0.001
sALCL ALK+	0	0	6 (18%)	27 (82%)	B2/C: *P*=0.001
PTCL-NOS	0	0	14 (70%)	6 (30%)	B/C: *P*<0.001
TCF-1					
LyP	7 (78%)	1 (11%)	1 (11%)	0	A/B: *P*=0.617
cALCL	5 (50%)	3 (30%)	2 (20%)	0	B1/B2: *P*<0.001
sALCL ALK-	12 (32%)*	17 (45%)*	5 (13%)*	4 (11%)*	B1/C: *P*<0.001
sALCL ALK+	27 (82%)	6 (18%)	0	0	B2/C: *P*<0.001
PTCL-NOS	0	0	19 (95%)	1 (5%)	B/C: *P*<0.001
TCF-1α/LEF-1					
LyP	6 (67%)	1 (11%)	2 (22%)	0	A/B: *P*=0.195
cALCL (n=9)	3 (33%)*	2 (22%)*	1 (11%)*	3 (33%)*	B1/B2: *P*<0.001
sALCL ALK-	15 (39%)	9 (24%)	6 (16%)	8 (21%)	B1/C: *P*=0.002
sALCL ALK+	32 (97%)	1 (3%)	0	0	B2/C: *P*<0.001
PTCL-NOS	1 (5%)	1 (5%)	12 (60%)	6 (30%)	B/C: *P*<0.001
Ets-1					
LyP	0	0	4 (44%)	5 (56%)	A/B: p <0.001
cALCL	0	2 (20%)	4 (40%)	4 (40%)	B1/B2 : *P*=0.947
sALCL ALK-	6 (16%)	12 (32%)	15 (39%)	5 (13%)	B1/C: *P*=0.170
sALCL ALK+	3 (9%)*	15 (45%)*	10 (30%)*	5 (15%)*	B2/C: *P*=0.119
PTCL-NOS	1 (5%)	4 (20%)	14 (70%)	1 (5%)	B/C: *P*=0.111
LAT					
LyP	4 (44%)*	4 (44%)*	1 (11%)*	0	A/B: *P*=0.964
cALCL	7 (70%)	1 (10%)	2 (20%)	0	B1/B2: *P*=0.589
sALCL ALK-	19 (50%)	16 (42%)	3 (8%)	0	B1/C: *P*<0.001
sALCL ALK+	18 (55%)	14 (42%)	1 (3%)	0	B2/C: *P*<0.001
PTCL-NOS	0	0	12 (60%)	8 (40%)	B/C: *P*<0.001
ZAP-70					
LyP	1 (11%)	0	6 (67%)	2 (22%)	A/B: *P*=0.004
cALCL	0	2 (20%)	4 (40%)	4 (40%)	B1/B2: *P*=0.139
sALCL ALK-	9 (24%)	8 (21%)	14 (37%)	7 (18%)	B1/C: *P*=0.004
sALCL ALK+	13 (39%)*	6 (18%)*	11 (33%)*	3 (9%)*	B2/C: *P*<0.001
PTCL-NOS	1 (5%)	0	10 (50%)	9 (45%)	B/C: *P*<0.001
Syk					
LyP	6 (67%)	1 (11%)	0	2 (22%)	A/B: *P*=0.348
cALCL (n=9)	6 (67%)	3 (33%)	0	0	B1/B2: *P*=0.006
sALCL ALK-	27 (71%)	4 (11%)	7 (18%)	0	B1/C: *P*=0.008
sALCL ALK+	12 (36%)*	9 (27%)*	11 (33%)*	1 (3%)*	B2/C: *P*<0.001
PTCL-NOS	20 (100%)	0	0	0	B/C: *P*<0.001
NFATc1					
LyP	2 (22%)*	1 (11%)*	3 (33%)*	3 (33%)*	A/B: *P*=0.001
cALCL	2 (20%)	3 (30%)	1 (10%)	4 (40%)	B1/B2: *P*=0.126
sALCL ALK-	15 (39%)*	14 (37%)*	7 (18%)*	2 (5%)*	B1/C: *P*<0.001
sALCL ALK+	17 (52%)	14 (42%)	1 (3%)	1 (3%)	B2/C: *P*<0.001
PTCL-NOS	0	1 (5%)	9 (45%)	10 (50%)	B/C: *P*<0.001
bcl-10					
LyP	0	1 (11%)	7 (78%)	1 (11%)	A/B: *P*=0.015
cALCL	1 (10%)	0	5 (50%)	4 (40%)	B1/B2: *P*=0.005
sALCL ALK-	4 (11%)	5 (13%)	22 (58%)	7 (18%)	B1/C: *P*=0.456
sALCL ALK+	6 (18%)*	12 (36%)*	14 (42%)*	1 (3%)*	B2/C: *P*=0.025
PTCL-NOS	1 (5%)	3 (15%)	16 (80%)	0	B/C: *P*=0.450

Carma1					
LyP	0	0	5 (56%)	4 (44%)	A/B: *P*<0.001
cALCL	0	0	4 (40%)	6 (60%)	B1/B2: *P*=0.582
sALCL ALK-	2 (5%)	5 (13%)	27 (71%)	4 (11%)	B1/C: *P*=0.221
sALCL ALK+	2 (6%)	6 (18%)	22 (67%)	3 (9%)	B2/C: *P*=0.109
PTCL-NOS	0	2 (10%)	15 (75%)	3 (15%)	B/C: *P*=0.120
Lck					
LyP (n=8)	4 (50%)*	0	3 (38%)*	1 (11%)*	A/B: *P*<0.001
cALCL	7 (70%)	1 (10%)	2 (20%)	0	B1/B2: *P*=0.102
sALCL ALK-	35 (92%)	2 (5%)	1 (3%)	0	B1/C: *P*<0.001
sALCL ALK+	33 (100%)	0	0	0	B2/C: *P*<0.001
PTCL-NOS	0	1 (5%)	5 (25%)	14 (70%)	B/C: *P*<0.001
c-Jun					
LyP (n=7)	0	2 (29%)	4 (57%)	1 (14%)	A/B: *P*=0.387
cALCL (n=9)	1 (11%)*	4 (44%)*	4 (44%)*	0	A/B: *P*=0.387
sALCL ALK- (n=36)	7 (19%)*	12 (33%)*	7 (19%)*	10 (28%)*	B1/B2: *P*=0.070
sALCL ALK+	2 (6%)*	6 (18%)*	15 (45%)*	10 (30%)*	B1/C: *P*<0.001
PTCL-NOS (n=12)	12 (100%)	0	0	0	B2/C: *P*<0.001
c-Fos					
LyP (n=7)	1 (14%)*	1 (14%)*	1 (14%)*	4 (57%)*	A/B: *P*=0.026
cALCL (n=9)	3 (33%)	5 (56%)	0	1 (11%)	B1/B2: *P*<0.001
sALCL ALK- (n=36)	12 (33%)	5 (14%)	8 (22%)	11 (31%)	B1/C: *P*<0.001
sALCL ALK+	0	0	2 (6%)	31 (94%)	B2/C: *P*<0.001
PTCL-NOS (n=12)	12 (100%)	0	0	0	B/C: *P*<0.001

Sum of percentages does not equal 100% due to rounding effects.

Online Supplementary Table S3. Complete raw data including the results of all stains in all cases (Case No = internal case numbers, Dx1 = Diagnostic group for statistical analysis, Dx2 = Diagnosis according to the World Health Organization classification, Dx3 = subgroup of the primary cutaneous CD30⁺ lymphoproliferative disorders; c = cytoplasmic, G = Golgi complex/endoplasmic reticulum, m = membranous staining pattern, n.d. = not done due to limited material. LyP, lymphomatoid papulosis; sALCL, systemic ALCL; cALCL, cutaneous ALCL.

Case No	Dx1	Dx2	Dx3	ALK	ATF-1	ATF-2	TCF-1	LEF-1	Ets-1	TCRβ	CD3γ	CD3ε	CD3δ	CD3ζ	LAT	ZAP-70	Syk	Lck	NFATc1	c-Fos	c-Jun	bcl10	CARMA1
A1	A1	Lyp	A		3	3	0	0	3	0	2c	2c	1c	1c	1	2	3	3	3	3	2	2	3
A2	A1	Lyp	A		3	3	0	0	3	0	0	0	0	1c	0	2	0	0	1	3	2	2	2
A3	A1	Lyp	A		3	3	0	0	2	1c	2c	2c	2c	1c	2	2	0	2	2	2	2	2	3
A4	A1	Lyp	A		3	3	1	2	2	2c	0	0	0	0	0	0	0	0	0	0	3	2	2
A5	A1	Lyp	A		3	3	0	0	2	0	0	0	0	1c	0	2	3	0	0	3	1	2	2
A6	A1	Lyp	A	n.d.	3	0	0	3	2c	1c	2cm	2c	1c	1	2	0	n.d.	2	n.d.	n.d.	1	2	
A7	A1	Lyp	A		2	3	0	1	3	0	0	0	1c	1c	1	2	0	0	2	3	2	2	2
A8	A1	Lyp	C		2	3	0	0	3	1c	0	1c	1c	1c	1	3	1	2	3	1	1	2	3
A9	A1	Lyp	C		3	3	2	2	2	1c	1c	3c	1c	1c	0	3	0	2	3	n.d.	n.d.	3	3
A10	A2	cALCL	Lyp-like		3	3	0	0	2	1c	0	1c	0	2c	2	3	1	0	3	1	2	2	3
A11	A2	cALCL	Lyp-like		3	3	0	n.d.	2	1c	1c	1c	1c	1c	0	2	n.d.	0	1	2		2	2
A12	A2	cALCL	Lyp-like		3	3	0	0	3	0	1c	1c	2c	1c	0	2	0	2	1	1	1	2	3
A13	A2	cALCL	Lyp-like		3	3	1	1	2	2c	3c	3c	3c	2cm	2	1	0	2	1	3	2	2	3
A14	A2	cALCL			2	3	2	3	3	0	1c	2cm	2c	0	1	2	1	1	3	1	2	3	3
A15	A2	cALCL			3	3	1	2	1	0	0	0	0	0	0	2	1	0	2	0	0	3	2
A16	A2	cALCL			3	3	0	1	3	0	0	0	0	1c	0	3	0	0	3	1	1	3	3
A17	A2	cALCL			3	3	0	0	2	1c	0	0	0	1c	0	1	0	0	0	1	1	0	3
A18	A2	cALCL			3	3	1	3	1	0	0	0	0	0	0	3	0	0	0	0	1	3	2
A19	A2	cALCL			3	3	2	3	2	2c	2c	3c	2c	2c	0	3	0	0	3	0	2	2	2
B1	B1	sALCL		ALK-	3	3	0	1	1	1c	3c	3c	3c	1c	1	2	0	0	0	1	1	0	2
B2	B1	sALCL		ALK-	2	3	3	1	3	2c	0	2c	0	3c	1	3	0	0	0	3	2	2	3
B3	B1	sALCL		ALK-	2	3	1	0	3	1c	0	0	0	0	0	2	0	0	2	3	3	0	2
B4	B1	sALCL		ALK-	2	3	1	1	2	2c	1cG	0	1cG	3c	0	3	2	0	0	2	2	2	2
B5	B1	sALCL		ALK-	2	3	1	0	2	0	0	0	0	1c	1	1	2	0	1	3	1	1	2
B6	B1	sALCL		ALK-	3	3	1	0	1	1c	0	2G	2c	1c	0	2	0	0	2	0	0	2	2
B7	B1	sALCL		ALK-	3	3	0	0	2	1c	1c	1c	1c	2c	1	2	1	1	1	1	3	2	2
B8	B1	sALCL		ALK-	3	3	1	0	0	0	1c	0	1c	0	0	2	0	0	0	0	0	2	2
B9	B1	sALCL		ALK-	2	3	0	0	2	0	0	0	0	0	0	0	0	0	0	3	1	2	2
B10	B1	sALCL		ALK-	2	3	1	3	3	0	3c	3c	3c	2c	0	2	0	2	3	0	0	1	2
B11	B1	sALCL		ALK-	3	3	1	2	0	0	1c	2c	2c	1G	0	0	2	0	0	0	1	3	2
B12	B1	sALCL		ALK-	3	3	0	0	2	0	0	0	0	0	0	2	0	0	0	2	3	0	3
B13	B1	sALCL		ALK-	3	3	0	0	0	0	0	0	0	0	1	0	2	0	0	0	1	0	2
B14	B1	sALCL		ALK-	2	3	0	0	1	2c	0	0	0	2c	2	1	2	0	0	3	3	2	3
B15	B1	sALCL		ALK-	3	3	0	0	1	1c	0	0	1c	3c	2	2	1	0	1	2	2	2	1
B16	B1	sALCL		ALK-	2	3	1	2	1	1c	0	1c	0	0	1	1	0	0	1	2	1	2	1
B17	B1	sALCL		ALK-	3	3	0	0	2	n.d.	0	0	0	1c	1	0	0	0	1	3	1	2	2
B18	B1	sALCL		ALK-	3	3	2	2	0	1c	0	0	0	1c	0	3	1	0	3	3	3	2	0
B19	B1	sALCL		ALK-	3	3	3	3	2	2c	3c	1cm	2c	2c	0	3	0	1	1	0	1	3	2
B20	B1	sALCL		ALK-	2	3	1	2	2	0	0	0	0	0	1	2	0	0	2	0	0	2	2
B21	B1	sALCL		ALK-	3	3	2	2	3	0	0	2cm	1c	1c	2	0	0	0	2	1	1	2	2
B22	B1	sALCL		ALK-	3	3	3	3	1	0	3c	3cm	2c	2G	0	2	0	0	1	0	2	2	2
B23	B1	sALCL		ALK-	2	3	2	3	0	0	0	0	0	0	0	0	2	0	0	2	3	3	2
B24	B1	sALCL		ALK-	3	3	0	0	2	0	0	0	0	0	0	1	0	0	0	3	1	2	0
B25	B1	sALCL		ALK-	3	3	1	1	1	1c	0	0	1c	1c	1	0	0	0	1	0	1	2	2
B26	B1	sALCL		ALK-	2	2	3	3	0	0	0	0	0	1c	1	3	0	0	1	0	0	3	2
B27	B1	sALCL		ALK-	3	3	1	1	1	0	2c	3c	1c	0	1	1	1	0	2	2	2	3	2
B28	B1	sALCL		ALK-	3	3	0	1	3	0	0	0	0	1G	0	3	0	0	1	2	2	3	1
B29	B1	sALCL		ALK-	3	3	1	1	2	0	0	0	0	0	1	0	0	0	0	3	1	1	1

ID	Subgroup	Dx	ALK	V1	V2	V3	V4	V5	V6	V7	V8	V9	V10	V11	V12	V13	V14	V15	V16	V17	V18	V19
B30	B1	sALCL	ALK-	2	3	2	2	2	0	0	3c	0	0	0	1	0	0	0	3	3	2	1
B31	B1	sALCL	ALK-	2	3	1	0	2	1c	1c	0	1c	1c	1	2	0	0	2	3	3	1	2
B32	B1	sALCL	ALK-	3	2	2	0	2	1c	0	0	0	1c	1	2	0	0	2	0	0	2	2
B33	B1	sALCL	ALK-	3	3	1	3	1	0	0	2c	0	0	0	3	2	0	0	1	2	3	3
B34	B1	sALCL	ALK-	2	3	1	1	2	1c	0	0	0	0	1	0	0	0	0	2	3	2	2
B35	B1	sALCL	ALK-	2	3	0	1	1	0	1c	0	1c	2c	0	1	0	0	1	3	3	2	2
B36	B1	sALCL	ALK-	3	3	1	3	1	0	0	0	0	2c	1	2	0	0	1	0	0	2	2
B37	B1	sALCL	ALK-	3	3	1	3	1	n.d.	0	1c	2c	1c	0	2	0	0	1	0	2	2	2
B38	B1	sALCL	ALK-	2	2	0	0	2	0	0	0	0	2c	0	1	0	0	1	1	1	1	2
B39	B2	sALCL	ALK+	3	3	0	0	1	0	0	2c	0	0	0	0	0	0	0	3	3	0	2
B40	B2	sALCL	ALK+	3	3	1	0	2	0	0	0	0	1c	1	0	1	0	1	3	3	1	2
B41	B2	sALCL	ALK+	3	3	0	0	2	0	0	0	0	1G	0	2	1	0	3	3	0	0	2
B42	B2	sALCL	ALK+	2	3	1	0	3	0	1c	1c	2c	0	1	2	2	0	1	3	2	2	3
B43	B2	sALCL	ALK+	3	3	0	0	1	0	0	0	0	0	0	2	2	0	1	3	1	1	2
B44	B2	sALCL	ALK+	2	2	0	0	1	0	0	0	1c	0	1	2	0	0	1	3	3	2	2
B45	B2	sALCL	ALK+	3	3	0	0	1	0	0	0	0	0	0	0	2	0	0	3	3	1	2
B46	B2	sALCL	ALK+	3	3	0	0	1	0	0	0	0	0	0	1	0	0	0	3	2	1	2
B47	B2	sALCL	ALK+	3	3	0	0	0	0	0	2cG	0	0	0	0	0	0	0	3	2	1	0
B48	B2	sALCL	ALK+	3	3	0	0	1	0	0	0	0	1G	1	1	2	0	0	3	2	2	2
B49	B2	sALCL	ALK+	3	3	0	0	1	0	0	0	0	0	0	0	0	0	0	3	3	2	1
B50	B2	sALCL	ALK+	3	3	0	0	1	0	1c	1c	2c	2c	1	1	1	0	1	2	0	1	1
B51	B2	sALCL	ALK+	3	3	0	0	2	1c	1c	1cm	2c	1c	1	2	2	0	1	3	2	1	3
B52	B2	sALCL	ALK+	3	3	0	0	1	0	0	0	0	0	0	0	1	0	0	3	1	0	2
B53	B2	sALCL	ALK+	2	3	1	0	3	0	0	0	0	2c	1	2	1	0	1	3	2	2	3
B54	B2	sALCL	ALK+	3	3	0	0	0	1c	0	0	0	0	2	1	0	0	0	3	3	2	2
B55	B2	sALCL	ALK+	2	3	1	0	1	0	2c	2c	3c	2c	1	3	2	0	1	3	2	2	2
B56	B2	sALCL	ALK+	3	3	0	0	0	1c	0	0	0	0	0	0	0	0	0	3	3	1	1
B57	B2	sALCL	ALK+	1	3	1	0	1	0	0	0	0	0	0	0	1	0	0	3	1	1	2
B58	B2	sALCL	ALK+	3	3	0	0	3	0	0	2c	2c	1c	0	3	2	0	2	3	1	3	2
B59	B2	sALCL	ALK+	2	3	0	0	2	0	0	0	0	0	0	0	2	0	0	3	3	2	2
B60	B2	sALCL	ALK+	3	3	0	0	2	1c	0	0	0	0	1	2	0	0	1	3	2	2	2
B61	B2	sALCL	ALK+	3	3	0	0	2	0	0	1c	0	0	0	0	2	0	0	3	2	2	2
B62	B2	sALCL	ALK+	2	3	0	0	1	0	1c	0	1c	0	0	0	0	0	0	3	3	0	1
B63	B2	sALCL	ALK+	2	2	0	0	2	0	0	0	0	0	0	0	0	0	0	3	2	1	0
B64	B2	sALCL	ALK+	1	2	0	0	2	0	0	1c	0	0	1	2	1	0	0	3	2	1	1
B65	B2	sALCL	ALK+	2	3	0	1	2	1c	0	0	0	1c	1	1	1	0	1	3	2	2	2
B66	B2	sALCL	ALK+	2	3	1	0	3	0	0	1c	0	2c	1	2	3	0	1	3	1	2	2
B67	B2	sALCL	ALK+	2	2	0	0	3	0	0	0	2c	1G	2G	0	3	2	0	1	3	2	2
B68	B2	sALCL	ALK+	2	3	0	0	1	0	0	0	0	0	1	1	0	0	0	2	2	0	1
B69	B2	sALCL	ALK+	2	3	0	0	2	0	0	0	0	1G	1	2	1	0	1	3	2	0	2
B70	B2	sALCL	ALK+	2	2	0	0	1	0	2c	2c	1c	1G	0	0	2	0	1	3	1	1	2
B71	B2	sALCL	ALK+	2	2	0	0	1	0	0	2c	0	0	0	2	0	0	0	3	3	2	2
C1	C	NOS		2	2	2	2	2	0	2	3	2	2	3	2	0	3	2	0	0	2	1
C2	C	NOS		2	2	2	3	2	0	3	3	2	2	3	3	0	3	3	0	0	2	2
C3	C	NOS		2	2	2	2	2	1	3	3	2	3	3	2	0	3	2	n.d.	n.d.	2	2
C4	C	NOS		2	3	2	3	2	3	2	3	2	2	2	2	0	3	2	0	0	2	2
C5	C	NOS		2	2	2	3	2	3	3	3	3	2	3	3	0	3	2	0	0	2	2
C6	C	NOS		2	3	2	2	2	2	2	2	2	2	2	2	0	3	3	0	0	2	2
C7	C	NOS		2	3	2	2	2	1	2	2	2	2	2	2	0	2	2	0	0	2	2
C8	C	NOS		2	2	2	2	2	2	2	3	2	2	2	2	0	3	2	0	0	2	2
C9	C	NOS		2	3	2	2	2	2	2	3	2	2	2	3	0	3	3	0	0	2	2
C10	C	NOS		2	2	2	3	3	3	3	3	3	3	2	2	0	2	3	0	0	2	2
C11	C	NOS		2	3	3	2	2	3	2	3	2	2	2	3	0	2	3	0	0	2	3
C12	C	NOS		2	2	2	2	2	3	3	3	2	3	3	3	0	3	3	0	0	1	2
C13	C	NOS		2	2	2	2	2	1	2	3	2	1	2	2	0	3	3	0	0	2	3
C14	C	NOS		3	3	2	0	1	n.d.	2	3	2	2	2	3	0	3	3	n.d.	n.d.	2	3
C15	C	NOS		2	2	2	2	2	n.d.	3	3	2	3	2	3	0	3	3	n.d.	n.d.	1	2
C16	C	NOS		3	2	2	1	0	n.d.	3	2	2	3	3	0	0	1	2	n.d.	n.d.	0	2
C17	C	NOS		2	2	2	3	1	n.d.	3	3	3	1	2	2	0	2	1	n.d.	n.d.	2	2
C18	C	NOS		2	2	2	2	2	n.d.	3	3	2	2	2	2	0	2	2	n.d.	n.d.	1	1
C19	C	NOS		2	2	2	3	1	2	3	3	3	2	3	3	0	3	3	n.d.	n.d.	2	2
C20	C	NOS		2	3	2	3	2	1	3	3	2	2	2	2	0	3	2	n.d.	n.d.	2	3